Sustained MRD Negativity With Cilta-Cel Leads to Deep Responses in Relapsed/Refractory Multiple Myeloma

Minimal residual disease negativity sustained for 6 months or longer with ciltacabtagene autoleucel prolonged duration of response and progression-free survival compared with minimal residual disease negativity sustained for less than 6 months in patients with heavily pretreated relapsed/refractory multiple myeloma.

Related Keywords

Houston ,Texas ,United States ,Yi Lin ,Thomasg Martin ,Ciltacabtagene Autoleucel ,Helen Diller Family Comprehensive Cancer Center ,Meeting Of The Society Hematologic Oncology ,Mayo Clinic ,Diller Family Comprehensive Cancer Center ,Annual Meeting ,Society Hematologic Oncology ,Heavily Pretreated Patients With ,Refractory Multiple ,Society Of Hematologic Oncology Annual Meeting Soho ,News ,Conference ,Multiple Myeloma ,2023 Soho Annual Meeting ,Nct03548207 ,Phase 1b 2 Cartitude 1 Study ,